18F-FDG PET/CT预测转移性去势敏感性前列腺癌激素治疗失败时间
这项前瞻性研究纳入76例转移性去势敏感性前列腺癌男性,于2005至2011年行18F-FDG PET/CT并随访至激素治疗失败(THTF,定义为改用化疗或死亡)。中位THTF为26.5个月(95%CI 15.5-46.6),5年无失败概率35%±6%。多变量分析显示仅SUVmax之和与病灶数目为THTF的独立预后因素。
要点
- SUVmax之和与病灶数目是转移性去势敏感性前列腺癌THTF的独立预后因素。
- SUVmax之和最高四分位组较最低组无失败生存显著更差,单因素HR 6.2(95%CI 2.8-13.6)。
- 中位THTF为26.5个月,5年无THTF概率为35%±6%。
核心结论
- 18F-FDG PET/CT得出的SUVmax之和与病灶数目可提供转移性去势敏感性前列腺癌THTF的独立预后信息。
研究设计与样本
- 前瞻性研究纳入2005至2011年76例转移性去势敏感性前列腺癌男性,行18F-FDG PET/CT并前瞻性随访THTF。
- THTF定义为改用化疗或死亡,未改用化疗者在末次随访时删失(中位36个月,范围12-108个月)。
- 采用Cox回归分析PET/CT指标(最多10个最活跃病灶的SUVmax之和、最大SUVmax、平均SUVmax)与THTF的关联,生存概率基于Kaplan-Meier法。
主要发现
- 43例出现激素治疗失败,8例死亡但无记录的治疗失败。
- 中位THTF为26.5个月(95%CI 15.5-46.6个月),5年无THTF概率为35%±6%。
- 单变量分析中所有PET参数(包括病灶数目)对THTF均有统计学意义。
- 校正临床变量的简化多变量模型中,仅SUVmax之和(HR 1.01;95%CI 1.002-1.03;P=0.024)与病灶数目(HR 1.18;95%CI 1.08-1.29;P<0.001)与THTF独立相关。
- SUVmax之和按四分位分组,第四分位组较第一分位组生存概率显著更差,单变量HR 6.2(95%CI 2.8-13.6;P<0.001)。
关键数值与推荐
- THTF定义为改用化疗或死亡。
- PET/CT测量指标为最多10个最活跃病灶的SUVmax之和、最大SUVmax和平均SUVmax。
- SUVmax之和每增加1单位HR 1.01(95%CI 1.002-1.03;P=0.024),病灶数目每增加1个HR 1.18(95%CI 1.08-1.29;P<0.001)。
临床怎么用
- 对转移性去势敏感性前列腺癌患者,18F-FDG PET/CT的SUVmax之和与病灶数目可用于辅助判断激素治疗失败风险。
- SUVmax之和处于最高四分位组的患者无THTF生存显著更差,提示可能需要更密切随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The aim of this prospective investigation was to assess the association of 18F-FDG PET/CT with time to hormonal treatment failure (THTF) in men with metastatic castration-sensitive prostate cancer. Methods: 76 men with metastatic castration-sensitive prostate cancer recruited from 2005 to 2011 underwent 18F-FDG PET/CT and were followed prospectively for THTF, defined as treatment change to chemotherapy or death. Patients who had not switched to chemotherapy were censored at the last follow-up date (median of 36 mo; range, 12-108 mo). Cox regression analyses were performed to examine the association between PET/CT measurements: sum of SUVmax, maximum SUVmax, and average SUVmax for up to 10 of the most active lesions and THTF. Survival probabilities were based on the Kaplan-Meier method. Results: 43 patients had hormonal treatment failure, and 8 died without documented treatment failure. Median THTF was 26.5 mo (95% confidence interval [CI], 15.5-46.6 mo). The THTF-free probability at 5 y was 35% ± 6%. On univariate analysis, all PET parameters, including number of lesions, were statistically significant for THTF. In a reduced multivariate model accounting for clinical variables, only sum of SUVmax (hazard ratio, 1.01; 95% CI, 1.002-1.03; P = 0.024) and number of lesions (hazard ratio, 1.18; 95% CI, 1.08-1.29; P < 0.001) were independently associated with THTF. When sum of SUVmax was grouped into quartile ranges, there was a significantly worse survival probability for patients in the fourth-quartile range than in the first, with a univariate hazard ratio of 6.2 (95% CI, 2.8-13.6; P < 0.001). Conclusion: Sum of SUVmax and number of lesions derived from 18F-FDG PET/CT provide independent prognostic information on THTF in men with metastatic castration-sensitive prostate cancer.
引用
- Jadvar H, Velez EM, Desai B, et al. Prediction of Time to Hormonal Treatment Failure in Metastatic Castration-Sensitive Prostate Cancer with 18F-FDG PET/CT. J Nucl Med. 2019. PMID: 30926649. doi:10.2967/jnumed.118.223263
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。